Selinexor for relapsed or refractory AML in combination treatments
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 60 years old
- Have AML that is either “refractory” (doesn’t respond) or “relapsed” (comes back) based on the trial’s timing and test rules
- Most people must have clear evidence of active bone marrow disease on a bone marrow scan (high activity or low production)
- Be able to do study tasks and clinic visits: physical status score (ECOG) must be 0–2
- Not have certain major conditions, like bleeding in the brain, pregnancy, serious heart rhythm problems, or an ECG QT interval over 500ms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two medicines, called selinexor and melphalan, twice a week after a stem cell transplant can help prevent acute myeloid leukemia from coming back. It's for people with high-risk AML who are 55 or older and whose cancer is in remission before the transplant.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests the drug selinexor as a single treatment to lower very high blood cell counts or shrink an enlarged spleen in patients with certain chronic blood cancers (polycythemia vera, essential thrombocythemia, or primary myelofibrosis). It may be an option if standard treatments are not working or cause side effects.
This phase 2 study tests whether doctors can choose the best AML treatment plan using a special blood/marrow test done on day 14. It may help people who are not good candidates for intensive chemotherapy by adjusting therapy based on early response.
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.